Maltese pot deal sets MGC Pharmaceuticals ablaze
Published 11-APR-2018 12:00 P.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
ASX pot-stock, MGC Pharmaceuticals (ASX:MXC), today revealed it has been awarded a contract by the Maltese government to construct a state-of-the-art medical cannabis production and cultivation facility spanning 4,000 square metres.
Following a competitive tender, MXC has emerged as one of only five companies — and the only one from Australia — to be awarded a full medical cannabis production and cultivation contract.
Having recently raised A$5 million (before costs) via a share placement to sophisticated and professional investors of 7 cents per share, MXC is nicely positioned to establish the production facility in accordance with the new contract.
This is a pivotal milestone for MXC, and comes on the heels of another high-impact announcement: MXC’s production of the first batch of CannEpilTM, following the receipt of its interim Good Manufacturing Practice (GMP) certification.
Under the agreement, MXC will be able to produce all THC (tetrahydrocannabinol) and CBD (cannabidiol) strains of medical cannabis at the facility. This expands MXC’s commercial opportunity to develop additional medical cannabis pharmaceutical products into key European and global markets, which derive benefits from both THC and CBD.
Pot produced at the facility will be used in the production of MXC’s Good Manufacturing Practice (GMP)-grade pharmaceutical products for major global markets including Australia, and will enable the supply of medical cannabis flowers directly into the emerging European markets, including Germany.
Securing this contract will complete MXC’s strategic plan to establish a fully vertically integrated medical cannabis ‘seed to sale’ operation in the European Union.
MXC will be required to comply with its licences and permits to operate the facility, including employing 25 Maltese people as part of the local workforce.
Malta is now in the final stages of legislative change with regard to medical cannabis laws. These changes will not only allow companies to produce medicinal cannabis in Malta, but also to export the medicine to other European countries where it is legal.
MXC is also set to tap a buzzing market with this deftly engineered deal. According to the European Cannabis Report 2017, with a market of over 739 million people, and total healthcare spend of €1.49 trillion, Europe will be the largest medical cannabis market in the world. The estimated cannabis market value per year in the EU is €56.2 billion.
However, how much of the market MXC is able to corner is speculative at this stage and, therefore, investors shouldn’t act on this fact alone, but should take all publicly available information into account and seek professional financial advice.
MGC Pharmaceuticals co-founder and CEO, Roby Zomer, said: “This contract provides MXC with an attractive new cultivation site in the European Union, completing the board’s strategy to operate a full vertically-integrated medical cannabis operation in Europe.
“Excitingly, with any CBD and THC strains of medical cannabis permitted under the agreement, we are now able to develop additional pharmaceutical products, which use the benefits of both CBD and THC.
“In addition to being used in the production of MXC’s GMP-certified pharmaceutical products, this contract extends the medical cannabis market for MXC into the supply of medical cannabis flowers to emerging European markets, including Germany,” added Zomer.
This latest development has seen share price highs this morning for MXC, currently sitting at 8.4 cents.
Past performance is not necessarily indicative of future results. As part of the due diligence process, investors must consider all factors over and above the past performance of the product. Investors should not engage with a product solely on it past performance.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
